Literature DB >> 16546416

Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations.

Lei Wan1, Chin-Moo Hsu, Chang-Hai Tsai, Cheng-Chun Lee, Wuh-Liang Hwu, Fuu-Jen Tsai.   

Abstract

Gaucher disease, the most prevalent lysosomal storage disease characterized by a remarkable degree of clinical variability, results from deleterious mutations in the beta-glucosidase gene. Although >200 mutations in the gene for human beta-glucosidase have been described, most genotype/phenotype studies have focused on screening for a few common mutations. In the present study, whole gene sequencing analysis was performed. We sequenced eight patients with type 1, five patients with type 2, and six patients with type 3 Gaucher disease in Taiwan. A total of 37 Gaucher chromosome were identified. The detection rate is 97%. For types 1 and 3 Gaucher disease, 1448 T > C (L444P) account for 53.5% Gaucher chromosome and the recombinant allele [1448 T > C, 1483 T > G, 1497 G > C] (RecNciI) has 25% prevalence rate among those patients. For type 2 Gaucher disease, all five patients carry L444P mutation, and RecNciI is found in two of the six patients. Because L444P is also present in the RecNciI mutation, all the patients in this study have a L444P mutation in their Gaucher chromosomes. The third most common mutation of type 1 Gaucher disease is 475 C > T (R120W). L444P homozygote and R120W/RecNciI genotypes are associated with non-neuronopathic Gaucher disease. RecNciI is related to neuronopathic disease, while R120W is represented as a mild mutation in Taiwan. The mutation profile of Gaucher disease in Taiwan is limited. Only four different alleles were identified in types 1 and 3 as well as in type 2 Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546416     DOI: 10.1016/j.bcmd.2006.02.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  17 in total

Review 1.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

2.  The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease.

Authors:  Usha Gutti; Hon-Chung Fung; Kathleen S Hruska; Mary E Lamarca; Chiung-Mei Chen; Yih-Ru Wu; Ellen Sidransky
Journal:  Arch Neurol       Date:  2008-06

3.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

4.  Screening of the glucocerebrosidase (GBA) gene in South Africans of African ancestry with Parkinson's disease.

Authors:  Amokelani C Mahungu; David G Anderson; Anastasia C Rossouw; Riaan van Coller; Jonathan A Carr; Owen A Ross; Soraya Bardien
Journal:  Neurobiol Aging       Date:  2019-12-20       Impact factor: 4.673

5.  A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders.

Authors:  Hamid Saranjam; Sameer S Chopra; Harvey Levy; Barbara K Stubblefield; Emerson Maniwang; Ian J Cohen; Hagit Baris; Ellen Sidransky; Nahid Tayebi
Journal:  Eur J Hum Genet       Date:  2012-06-20       Impact factor: 4.246

6.  Novel mutations in the glucocerebrosidase gene of Indian patients with Gaucher disease.

Authors:  Chitra Ankleshwaria; Mehul Mistri; Ashish Bavdekar; Mamta Muranjan; Usha Dave; Parag Tamhankar; Varun Khanna; Eresha Jasinge; Sheela Nampoothiri; Suresh Edayankara Kadangot; Frenny Sheth; Sarita Gupta; Jayesh Sheth
Journal:  J Hum Genet       Date:  2014-02-13       Impact factor: 3.172

7.  Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.

Authors:  J Cox-Brinkman; M J van Breemen; B T van Maldegem; L Bour; W E Donker; C E M Hollak; F A Wijburg; J M F G Aerts
Journal:  J Inherit Metab Dis       Date:  2008-10-15       Impact factor: 4.982

8.  Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.

Authors:  Shira G Ziegler; Michael J Eblan; Usha Gutti; Kathleen S Hruska; Barbara K Stubblefield; Ozlem Goker-Alpan; Mary E LaMarca; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2007-04-25       Impact factor: 4.797

Review 9.  Gaucher disease: new developments in treatment and etiology.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

10.  Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese.

Authors:  Yih-Ru Wu; Chiung-Mei Chen; Chih-Ying Chao; Long-Sun Ro; Rong-Kuo Lyu; Kuo-Hsuan Chang; Guey-Jen Lee-Chen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.